NCT06027073 (BSIPL) is a Phase 4 clinical trial of omalizumab in Asthma, Allergic, sponsored by Medical University of Silesia.

Who is sponsoring NCT06027073?

NCT06027073 is sponsored by Medical University of Silesia.

What drugs are being tested in NCT06027073?

Interventions in NCT06027073: omalizumab.

What condition does NCT06027073 study?

NCT06027073 studies Asthma, Allergic.

Is NCT06027073 still recruiting?

NCT06027073 is currently not yet recruiting. Last updated 7 September 2023.

Last reviewed 2023-09-07 · How we verify

NCT06027073: BSIPL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biologics and Sublingual Immunotherapy

Not yet recruiting Phase 4 Last updated 7 September 2023

What this trial tests

Phase 4 trial testing omalizumab in Asthma, Allergic in 150 participants. Not yet recruiting.

Timeline

1 May 2024

Primary endpoint
1 October 2026

1 March 2028

Quick facts

Lead sponsor	Medical University of Silesia
Phase	Phase 4
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	150
Start date	1 May 2024
Primary completion	1 October 2026
Estimated completion	1 March 2028

Drugs / interventions tested

omalizumab (omalizumab) — full drug profile →

Conditions studied

Asthma, Allergic — all drugs for Asthma, Allergic →

Sponsor

Medical University of Silesia

Who can join

Adults 18 to 65, any sex, with Asthma, Allergic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Most current studies involve using a biological drug to increase the safety of allergen immunotherapy (AIT) especially in the treatment of food allergies, to avoid the risk of anaphylaxis. However, adding Xolair® to AIT may improve the therapy's effectiveness. There are still few observations on this topic, especially in patients with house dust mite (HDM)-driven asthma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Allergen Immunotherapy for the Prevention and Treatment of Asthma.
Batard T, Taillé C, Guilleminault L, Bozek A, et al · · 2025 · cited 13× · PMID 39363801 · DOI 10.1111/cea.14575

Verify or expand the search:

Other trials of omalizumab

Trials testing the same drug.

NCT06771934 — Combination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe Asthma · active not recruiting
NCT04943744 — Gastrointestinal STRING Test With Oral Immunotherapy · EARLY_PHASE1 · terminated
NCT02161562 — OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Pa · Phase 3 · completed
NCT02388997 — Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With Rhinovirus · Phase 2 · completed

Other recruiting trials for Asthma, Allergic

Currently open trials in the same condition.

NCT03455959 — Lung-Resident Memory Th2 Cells in Asthma · NA · active not recruiting

Other Medical University of Silesia trials

Trials by the same sponsor.

NCT06212674 — Single-stage Pulmonary Vein Isolation Combined With Percutaneous Left Atrial Appendage Occluder Implantation in Patients · Phase 4 · recruiting
NCT06970002 — Respiratory Stabilization in Chronic Acidosis Before Bronchofiberoscopy & Non-Invasive Ventilation Effectivenes · NA · not yet recruiting
NCT07137299 — POPQ Associated With Total Laparoscopic Hysterectomy · not yet recruiting
NCT06970041 — To Assess the Types of Mechanical Ventilation in Enabling Therapeutic Bronchofiberoscopy in Patients With Decompensated · NA · not yet recruiting
NCT07120529 — Minimally Invasive Surgery Versus Open Radical Hysterectomy in Presumably Early Stage Cervical Cancer: a Retrospective M · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06027073 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Silesia
Last refreshed: 7 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06027073.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing